LENSAR, Inc. develops and markets robotic laser systems for cataract treatment and astigmatism management. The company’s product portfolio includes the ALLY Robotic Cataract Laser System, the LENSAR Laser System with Streamline IV and IntelliAxis, related software, and associated consumable components.
Recurring company updates focus on ALLY system placements, installed-base activity, procedure volume, and recurring revenue from procedure, lease, and service sources. LENSAR news also includes quarterly and annual results, medical-device regulatory disclosures, material agreements, capital-structure matters, and governance actions such as equity inducement awards.
LENSAR, Inc. (NASDAQ: LNSR) has officially completed its spin-off from PDL BioPharma, Inc. (NASDAQ: PDLI), with shares beginning regular trading on NASDAQ. The distribution grants PDL stockholders 0.075879 shares of LENSAR for each share of PDL held as of September 22, 2020. LENSAR specializes in femtosecond laser surgical solutions for cataract treatment, utilizing advanced technologies to enhance surgical outcomes.